This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6tgg
From Proteopedia
(Difference between revisions)
m (Protected "6tgg" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==scFv-1SM3 in complex with glycopeptide containing an sp2-imino sugar== | |
| - | + | <StructureSection load='6tgg' size='340' side='right'caption='[[6tgg]], [[Resolution|resolution]] 2.00Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6tgg]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TGG OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TGG FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=N8W:~{N}-[(6~{S},7~{R},8~{S},8~{a}~{R})-7,8-bis(oxidanyl)-3-oxidanylidene-1,5,6,7,8,8~{a}-hexahydro-[1,3]oxazolo[3,4-a]pyridin-6-yl]ethanamide'>N8W</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tgg FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tgg OCA], [http://pdbe.org/6tgg PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tgg RCSB], [http://www.ebi.ac.uk/pdbsum/6tgg PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tgg ProSAT]</span></td></tr> |
| + | </table> | ||
| + | == Disease == | ||
| + | [[http://www.uniprot.org/uniprot/MUC1_HUMAN MUC1_HUMAN]] Note=MUC1/CA 15-3 is used as a serological clinical marker of breast cancer to monitor response to breast cancer treatment and disease recurrence (PubMed:20816948). Decreased levels over time may be indicative of a positive response to treatment. Conversely, increased levels may indicate disease progression. At an early stage disease, only 21% of patients exhibit high MUC1/CA 15-3 levels, that is why CA 15-3 is not a useful screening test. Most antibodies target the highly immunodominant core peptide domain of 20 amino acid (APDTRPAPGSTAPPAHGVTS) tandem repeats. Some antibodies recognize glycosylated epitopes. | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/MUC1_HUMAN MUC1_HUMAN]] The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.<ref>PMID:9139698</ref> <ref>PMID:11877440</ref> <ref>PMID:14688481</ref> <ref>PMID:15710329</ref> <ref>PMID:16288032</ref> <ref>PMID:15513966</ref> <ref>PMID:17524503</ref> <ref>PMID:17308127</ref> <ref>PMID:16983337</ref> The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity.<ref>PMID:9139698</ref> <ref>PMID:11877440</ref> <ref>PMID:14688481</ref> <ref>PMID:15710329</ref> <ref>PMID:16288032</ref> <ref>PMID:15513966</ref> <ref>PMID:17524503</ref> <ref>PMID:17308127</ref> <ref>PMID:16983337</ref> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Avenoza, A]] | ||
| + | [[Category: Bermejo, I A]] | ||
| + | [[Category: Bernardes, G J.L]] | ||
| + | [[Category: Busto, J H]] | ||
| + | [[Category: Castro-Lopez, J]] | ||
| + | [[Category: Corzana, F]] | ||
| + | [[Category: Garcia-Fernandez, J M]] | ||
| + | [[Category: Garcia-Martin, F]] | ||
| + | [[Category: Guerreiro, A]] | ||
| + | [[Category: Hurtado-Guerrero, R]] | ||
| + | [[Category: Navo, C D]] | ||
| + | [[Category: Nishimura, S I]] | ||
| + | [[Category: Ortiz-Mellet, C]] | ||
| + | [[Category: Peregrina, J M]] | ||
| + | [[Category: Samchez-Fernandez, E M]] | ||
| + | [[Category: Anti cancer vaccine]] | ||
| + | [[Category: Antibody]] | ||
| + | [[Category: Antigen tn]] | ||
| + | [[Category: Antitumor protein]] | ||
| + | [[Category: Conformational analysis]] | ||
| + | [[Category: Iminosugar]] | ||
| + | [[Category: Scfv]] | ||
Revision as of 06:55, 8 April 2020
scFv-1SM3 in complex with glycopeptide containing an sp2-imino sugar
| |||||||||||
Categories: Large Structures | Avenoza, A | Bermejo, I A | Bernardes, G J.L | Busto, J H | Castro-Lopez, J | Corzana, F | Garcia-Fernandez, J M | Garcia-Martin, F | Guerreiro, A | Hurtado-Guerrero, R | Navo, C D | Nishimura, S I | Ortiz-Mellet, C | Peregrina, J M | Samchez-Fernandez, E M | Anti cancer vaccine | Antibody | Antigen tn | Antitumor protein | Conformational analysis | Iminosugar | Scfv
